alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



Exhibit 31(a) REPUBLIC BANCORP INC.
Certification of the Principal Executive Officer
Pursuant to 15 U.S.C. 78m(a) or 78o(d)
(Section 302 of the Sarbanes-Oxley Act of 2002) I, Dana M. Cluckey, certify that:  1.
    
    I have reviewed this report on Form 10-Q of Republic Bancorp Inc;2.
    
    Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;4.
    
    The registrants other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
registrant and we have:  a)
    
    designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;b)
    
    evaluated the effectiveness of the registrants disclosure
controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; andc)
    
    disclosed in this report any change in the registrants
internal control over financial reporting that occurred during the
registrants most recent fiscal quarter (the registrants fourth
fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
registrants internal control over financial reporting; and  5.
    
    The registrants other certifying officer and I have disclosed, based
on our most recent evaluation of internal control over financial
reporting, to the registrants auditors and the audit committee of the
registrants board of directors (or persons performing the equivalent
functions):  a)
    
    all significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting
which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial
information; andb)
    
    any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrants
internal control over financial reporting. Date: August 6, 2004
    
    /s/ Dana M. CluckeyDana M. CluckeyPresident and Chief Executive Officer
Use Diagram

[ CBI ]
§ 640.30 Plasma. ( a ) *Proper name and definition.* The proper name of this component is Plasma. The component is defined as: ( 1 ) The fluid portion of one unit of human blood intended for intravenous use which is collected in a closed system, stabilized against clotting, and separated from the red cells; or
( 2 ) The fluid portion of human blood intended for intravenous use which is prepared by apheresis methods as specified in the directions for use for the blood collecting, processing, and storage system including closed and open systems.
( b ) *Source.* ( 1 ) Plasma shall be obtained by separating plasma from blood collected from blood donors or by plasmapheresis.
( 2 ) Plasma may be obtained from a unit of Whole Blood collected by another licensed establishment.
[42 FR 59878, Nov. 22, 1977; 48 FR 13026, Mar. 29, 1983, as amended at 50 FR 4139, Jan. 29, 1985; 72 FR 45888, Aug. 16, 2007]
Exhibit



 



PRIVATE AND CONFIDENTIAL




April 10, 2017


    
Craig S. Cocchi




RE:    Amendment to Offer of Employment Dated March 7, 2017 


Dear Craig:


I am pleased to confirm on behalf of Oclaro, Inc. (“Oclaro”) that subsequent to your acceptance of our offer to serve as Executive Vice President, Global Operations, our Board of Directors has approved your appointment to serve as Oclaro’s Chief Operating Officer, reporting to me.  


Except as set forth in this letter, all other terms and conditions of your offer letter dated March 7, 2017 will continue to remain in effect.  


Kindly acknowledge your acceptance of this appointment and agreement to the terms of this letter by signing the attached copy of this letter and returning it to me. 




Yours Sincerely, 





Greg Dougherty
CEO






ACKNOWLEDGED AND AGREED






Signed: /s/ Craig S. Cocchi
Date:    April 10, 2017
     Craig S. Cocchi                             






















Oclaro, Inc. | 225 Charcot Avenue, San Jose, CA 95131 | Tel: +1.408.383.1400                     www.oclaro.com
Editorial Note on Part 341
Editorial Note: Nomenclature changes to part 341 appear at 69 FR 13717, Mar. 24, 2004.

§ 341.1 Scope. ( a ) An over-the-counter cold, cough, allergy, bronchodilator, or antiasthmatic drug product in a form suitable for oral, inhalant, or topical administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this part and each of the general conditions established in § 330.1.
( b ) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.
[51 FR 35339, Oct. 2, 1986]
-1- 



    	 



    








    	-2- 



    	 



    








    	-3- 



    	 



    








    	-4- 



    	 



    








    	-5- 



    	 



    








    	-6- 



    	 



    








    	-7- 



    	 



    








    	-8- 



    	 



    








    	-9- 



    	 



    








    	-10- 



    	 



    








    	-11- 



    	 



    








    	-12-
**Exhibit23.1**

 

**Consent of Independent Registered Public AccountingFirm**

** **

The Board of Directors

LOUD Technologies Inc.:

 

We consent to the incorporation by reference in the registrationstatements (Nos. 33-98720 and 333-107060) on Form S-8 of LOUD Technologies Inc.of our report dated March 4, 2005, with respect to the consolidated balancesheets of LOUD Technologies Inc. as of December 31, 2004 and 2003, and the related consolidatedstatements of operations,  shareholders’equity and comprehensive loss and cash flows for each of the years in thethree-year period ended December 31, 2004, which report appears in theDecember 31, 2004, annual report on Form 10-K of LOUD Technologies Inc.  Our reportrefers to a change in the method of accounting for goodwill and other intangible assets as of January 1, 2002. 

 

 
| /s/  KPMG LLP        |
|----------------------|
|                 |
| Seattle,  Washington |
| March 31, 2005       |

 

1

----
Wyoming Sulfate Contribution to Lostwood

Worst

site Year modelrun param N SReg PT AF MV Nat Area Total

LOST1 2002 plan02c36k PS4 24 WY 0.0260833 8.33E-06 0.00165 0.0001083 0.0035625 0.0314125

Wyoming's 2002 Contribution (20% Worst) to Sulfate at Lostwood = 0.03 divided by 2.3, or 1%

Best

site Year modelrun param N SReg PT AF MV Nat Area Total

LOST1 2002 plan02c36k PS4 23 WY 0.0023652 4.35E-06 0.000287 4.35E-06 0.0005261 0.003187

Wyoming's 2002 Contribution (20% Best) to Sulfate at Lostwood = 0.003 divided by 1.1, or <1%
§ 573.380 Ethoxyquin in animal feeds. Ethoxyquin (1,2-dihydro-6-ethoxy-2,2,4-trimethylquinoline) may be safely used in animal feeds, when incorporated therein in accordance with the following prescribed conditions. ( a ) It is intended for use only: ( 1 ) As a chemical preservative for retarding oxidation of carotene, xanthophylls, and vitamins A and E in animal feed and fish food and,
( 2 ) as an aid in preventing the development of organic peroxides in canned pet food.
( b ) The maximum quantity of the additive permitted to be used and to remain in or on the treated article shall not exceed 150 parts per million.
( c ) To assure safe use of the additive, the label and labeling of the food additive container and that of any intermediate premixes prepared therefrom shall contain, in addition to other information required by the act: ( 1 ) The name of the additive, ethoxyquin.
( 2 ) A statement of the concentration or strength contained therein.
( 3 ) Adequate use directions to provide for a finished article with the proper concentration of the additive as provided in paragraph (b) of this section, whether or not intermediate premixes are to be used.
( d ) The label of any animal feed containing the additive shall, in addition to the other information required by the act, bear the statement “Ethoxyquin, a preservative” or “Ethoxyquin added to retard the oxidative destruction of carotene, xanthophylls, and vitamins A and E.”
1 

### Mears, Gilbert

From: Mickey Gniadek <mickeymaster@msn.com> Sent: Saturday, August 30, 2014 12:24 PM To: Mears, Gilbert

Follow Up Flag: Follow up Flag Status: Flagged

DOCKET #: EPA-HQ-TRI-2013-0281

Mr. Mears,

It is EXTREMELY IMPORTANT to myself regarding Toxic Release Inventory Program and Reporting as I was exposed on December 7th 2013 to Ch lorine and Methane Gas emitted from an EQT well site known as the TRAX Pad of Rte 88 in Findle3yville , PA 15332 also on another occasion their was a release of black smoke which my wife filmed and posted on a youtube video. This lasted well over a 4 and a half hour period. On both occasions I presented this to our borough council and in each case initially there was denial by the EQT representative along with a promise to get back to council with an explanantion which has NEVER been done and NOT persued by our Council. With th e second incident, that evening and the next day myself and many neighbors complained of severe head aches and a very foul odor of burning rotten eggs. This disclosure through T R I P is of great importance to myself and neighbors. If you have any further questions regarding these matters at yuour convenience please give me a call. Mickey Gniadek 20 Cardox Road Finleyville, PA 15332 412-835-2159. Unsure at this time what medical effects these releas es have had on me or my family and neighbors nor what the emissions were and the concentrations therein. Thank You in advance

Mickey Gniadek 412-835-2159
```

[Federal Register Volume 79, Number 60 (Friday, March 28, 2014)]
[Notices]
[Page 17637]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-06961]

-----------------------------------------------------------------------

DEPARTMENT OF STATE

[Public Notice 8676]

Culturally Significant Objects Imported for Exhibition 
Determinations: ``The World Is an Apple'': The Still Lifes of Paul 
C[eacute]zanne

SUMMARY: Notice is hereby given of the following determinations: 
Pursuant to the authority vested in me by the Act of October 19, 1965 
(79 Stat. 985; 22 U.S.C. 2459), Executive Order 12047 of March 27, 
1978, the Foreign Affairs Reform and Restructuring Act of 1998 (112 
Stat. 2681, et seq.; 22 U.S.C. 6501 note, et seq.), Delegation of 
Authority No. 234 of October 1, 1999, and Delegation of Authority No. 
236-3 of August 28, 2000 (and, as appropriate, Delegation of Authority 
No. 257 of April 15, 2003), I hereby determine that the objects to be 
included in the exhibition ``The World Is an Apple'': The Still Lifes 
of Paul C[eacute]zanne, imported from abroad for temporary exhibition 
within the United States, are of cultural significance. The objects are 
imported pursuant to loan agreements with the foreign owners or 
custodians. I also determine that the exhibition or display of the 
exhibit objects at The Barnes Foundation, Philadelphia, Pennsylvania, 
from on or about June 22, 2014, until on or about September 22, 2014, 
and at possible additional exhibitions or venues yet to be determined, 
is in the national interest. I have ordered that Public Notice of these 
Determinations be published in the Federal Register.

FOR FURTHER INFORMATION CONTACT: For further information, including a 
list of the imported objects, contact Paul W. Manning, Attorney-
Adviser, Office of the Legal Adviser, U.S. Department of State 
(telephone: 202-632-6469). The mailing address is U.S. Department of 
State, SA-5, L/PD, Fifth Floor (Suite 5H03), Washington, DC 20522-0505.

    Dated: March 24, 2014.
Kelly Keiderling,
Principal Deputy Assistant Secretary, Bureau of Educational and 
Cultural Affairs, Department of State.
[FR Doc. 2014-06961 Filed 3-27-14; 8:45 am]
BILLING CODE 4710-05-P
```
From the Desk of:

Richard Brown

Sr. Scientist

Innovative Imaging & Research

Stennis Space Center, MS

39529

228-688-1236

Sept. 18, 2015

Dear Mr. Daniels:

Having spoken to you on July 9, 2015 concerning the Request for Additional Information document 

Posted: 06/09/2015 ID: FAA-2015-0973-0002, I am posting this response formally to summarize our 

discussion. The above sited document was a copy of an email sent to the incorrect email address

(rbrown@i2corp.com not rbrown@i2rcorp.com as listed in the 333 Exemption documentation submitted).

I did not receive any email notification of the request for information. 

After discovering the PDF copy of the email on our online docket folder, I contacted you personally on 

July 9. Per our conversation on July 9, it was affirmed by you that the information requested in the above 

sited document was already included in Appendix A of the 333 Exemption documentation submitted by 

I2R and thus our 333 Exemption review would be moved on to the next part of the process by FAA.

Thank you for your assistance and attention in this matter and please call me at (228) -688-1236 if there 

are any further questions.

Best regards,

Richard Brown

rbrown@i2rcorp.com
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsWeber Number Tests in the NASA Icing Research TunnelA study of the Weber Number effects on droplets in the NASA Icing Research Tunnel is described. The work focuses on examining the droplet Weber Number effects observed for droplets accelerated by air flow in the contraction section of the Icing Research Tunnel to the test section. These results will aid in Supercooled Large Drop facility design studies. Measurements acquired with the Phase Doppler Interferometer and High Speed Imaging Dual Range Flight Probes at a series of locations through the contraction are presented alongside a 1D numerical model developed during this study to aid interpretation of the experimental results. An estimate of the maximum Weber Number observed in the Icing Research Tunnel for varying drop sizes up to 1000 μm is presented and provided for incorporation into future design studies. Finally, experimental results coupled with a numerical model indicate that breakup of drops up to 1000 μm is not occurring in the NASA Icing Research Tunnel up to 129 m/s.Document ID20190002785Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsKing, Michael C.*(NASA Glenn Research Center Cleveland, OH, United States)*Bachalo, William D.*(Artium Technologies, Inc. Sunnyvale, CA, United States)*Bell, Dwayne*(McKinley Climatic Lab. Eglin AFB, FL, United States)*King-Steen, Laura E.*(HX5 Sierra, LLC Cleveland, OH, United States)*Date AcquiredApril 26, 2019Publication DateApril 1, 2019Subject CategoryResearch And Support Facilities (Air)Numerical AnalysisReport/Patent NumberAIAA Paper 2018?3184E-19626GRC-E-DAA-TN62232NASA/TM-2019-220025Meeting InformationMeeting: AIAA Aviation ForumLocation: Atlanta, GACountry: United StatesStart Date: June 25, 2019End Date: June 29, 2019Sponsors:American Institute of Aeronautics and Astronautics (AIAA)Funding Number(s)CONTRACT_GRANT: SPEC5721CONTRACT_GRANT: SAA31506CONTRACT_GRANT: NNC15BA02BWBS: 147016.03.03.02.13.02Distribution LimitsPublicCopyrightPublic Use Permitted.Technical ReviewSingle ExpertKeywordsIcing Wind TunnelAirframe IcingWeber NumberAvailable DownloadsNameType20190002785.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Exhibit
31.1








I, Mary
G. Merritt, certify that:





1. I have
reviewed this annual report on Form 10-KSB of Preferred Voice,
Inc.;





2. Based
on my knowledge, this annual report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this annual
report;





3. Based
on my knowledge, the financial statements, and other financial information
included in this annual report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this annual report.





4. I am
responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and I
have:





a.
designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to me by others within those entities, particularly during the
period in which this annual report is being prepared;





b.
evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and





c.
presented in this annual report my conclusions about the effectiveness of the
disclosure controls and procedures based on my evaluation as of the Evaluation
Date;





5. I have
disclosed, based on our most recent evaluation, to the registrant's auditors and
the board of directors (or persons performing the equivalent
function):





a. all
significant deficiencies in the design or operation of internal controls which
could adversely affect the registrant's ability to record, process, summarize
and report financial data and have identified for the registrant's auditors any
material weaknesses in internal controls; and





b. any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant's internal controls; and





6. I have
indicated in this annual report whether or not there were significant changes in
internal controls or in other factors that could significantly affect internal
controls subsequent to the date of our most recent evaluation, including any
corrective actions with regard to significant deficiencies and material
weaknesses.










/s/ Mary G.
Merritt




Mary G.
Merritt


Chief
Financial Officer


(Principal
Executive Officer


and  Principal
Financial Officer)


July 11,
2008
# C_2015026EN.01001201.xml

| 26.1.2015 | EN | Official Journal of the European Union | C 26/12 |
| --- | --- | --- | --- |

26.1.2015

EN

Official Journal of the European Union

C 26/12

---

Request for a preliminary ruling from the Tribunale Regionale di Giustizia Amministrativa di Trento (Italy) lodged on 6 November 2014 — Antonio Tita and Others v Ministero della Giustizia and Others

(Case C-495/14)

(2015/C 026/15)

Language of the case: Italian

Referring court

Referring court

Tribunale Regionale di Giustizia Amministrativa di Trento

Parties to the main proceedings

Parties to the main proceedings

Applicants: Antonio Tita, Alessandra Carlin, Piero Constantini

Applicants:

Defendant: Ministero della Giustizia, Ministero dell’Economia e delle Finanze, Presidenza del Consiglio dei Ministri, Segretario Generale del Tribunale Regionale di Giustizia Amministrativa di Trento (TRGA)

Defendant:

Question referred

Question referred

Do the principles fixed by Directive 2007/66/EC of the European Parliament and of the Council of 11 December 2007 (1) and by Council Directives 89/665/EEC (2) and 92/13/EEC (3) , with regard to improving the effectiveness of review procedures concerning the award of public contracts, preclude a provision of national law, such as that on the lump sum payable in respect of court fees laid down in Articles 9, 13(6)bis and (6)bis1 and 14(3)ter of Decree of the President of the Republic No 115 of 30 May 2002 (as progressively amended by subsequent legislative interventions), and in Article 1(27) of Law No 228 of 24 December 2012, which laid down high amounts for the lump sum payable for access to administrative proceedings relating to public procurement procedures.

1

2

3

---

(1)  Directive 2007/66/EC of the European Parliament and of the Council of 11 December 2007 amending Council Directives 89/665/EEC and 92/13/EEC with regard to improving the effectiveness of review procedures concerning the award of public contracts (OJ 2007 L 335, p. 31).

1

(2)  Council Directive 89/665/EEC of 21 December 1989 on the coordination of the laws, regulations and administrative provisions relating to the application of review procedures to the award of public supply and public works contracts (OJ 1989 L 395, p. 33).

2

(3)  Council Directive 92/13/EEC of 25 February 1992 coordinating the laws, regulations and administrative provisions relating to the application of Community rules on the procurement procedures of entities operating in the water, energy, transport and telecommunications sectors (OJ 1992 L 76, p. 14).

3

---
§ 700.16 Use of aerosol cosmetic products containing zirconium. ( a ) Zirconium-containing complexes have been used as an ingredient in cosmetics and/or cosmetics that are also drugs, as, for example, aerosol antiperspirants. Evidence indicates that certain zirconium compounds have caused human skin granulomas and toxic effects in the lungs and other organs of experimental animals. When used in aerosol form, some zirconium will reach the deep portions of the lungs of users. The lung is an organ, like skin, subject to the development of granulomas. Unlike the skin, the lung will not reveal the presence of granulomatous changes until they have become advanced and, in some cases, permanent. It is the view of the Commissioner that zirconium is a deleterious substance that may render any cosmetic aerosol product that contains it injurious to users.
( b ) Any aerosol cosmetic product containing zirconium is deemed to be adulterated under section 601(a) of the Federal Food, Drug, and Cosmetic Act.
( c ) Any such cosmetic product introduced in interstate commerce after September 15, 1977 is subject to regulatory action.
[42 FR 41376, Aug. 16, 1977]